Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests

[1]  Soma Das,et al.  Scaling resolution of variant classification differences in ClinVar between 41 clinical laboratories through an outlier approach , 2018, Human mutation.

[2]  Patrick Callier,et al.  Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of prospective annual reanalysis , 2017, Genetics in Medicine.

[3]  K. Sangkuhl,et al.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.

[4]  Keith Nykamp,et al.  Sources of discordance among germ-line variant classifications in ClinVar , 2017, Genetics in Medicine.

[5]  Gil McVean,et al.  The 100,000 Genomes Project Protocol , 2017 .

[6]  Soma Das,et al.  Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.

[7]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[8]  R. Myers,et al.  Genomic diagnosis for children with intellectual disability and/or developmental delay , 2016, bioRxiv.

[9]  Stephen N. Thibodeau,et al.  Whole‐Genome Sequencing in Healthy People , 2017, Mayo Clinic proceedings.

[10]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[11]  Janet E Olson,et al.  Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. , 2016, The American journal of medicine.

[12]  W. Chung,et al.  Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.

[13]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[14]  I. Budin-Ljøsne,et al.  Patient and interest organizations’ views on personalized medicine: a qualitative study , 2016, BMC medical ethics.

[15]  D. Ledbetter,et al.  Recommendations for the integration of genomics into clinical practice , 2016, Genetics in Medicine.

[16]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[17]  Sheri D Schully,et al.  A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation , 2016, Genetics in Medicine.

[18]  D. Adams,et al.  Pharmacogenomic incidental findings in 308 families: The NIH Undiagnosed Disease Program experience , 2016, Genetics in Medicine.

[19]  Gert Matthijs,et al.  Guidelines for diagnostic next-generation sequencing , 2015, European Journal of Human Genetics.

[20]  J. Berg,et al.  A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing , 2015, Genetics in Medicine.

[21]  Laurie D. Smith,et al.  Whole-Exome Sequencing and Whole-Genome Sequencing in Critically Ill Neonates Suspected to Have Single-Gene Disorders. , 2016, Cold Spring Harbor perspectives in medicine.

[22]  Laurie D. Smith,et al.  Rapid whole genome sequencing and precision neonatology. , 2015, Seminars in perinatology.

[23]  Jaekyu Shin,et al.  Clinical application of pharmacogenetics: focusing on practical issues. , 2015, Pharmacogenomics.

[24]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[26]  Gail P Jarvik,et al.  The cost-effectiveness of returning incidental findings from next-generation genomic sequencing , 2014, Genetics in Medicine.

[27]  Xuan Yuan,et al.  Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.

[28]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[29]  L. Vissers,et al.  Genome sequencing identifies major causes of severe intellectual disability , 2014, Nature.

[30]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.

[31]  A. Rauch.  Exome sequencing in unspecific intellectual disability and rare disorders , 2014, Molecular Cytogenetics.

[32]  J. Vermeesch,et al.  Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. , 2014, Human reproduction.

[33]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[34]  Emily H Turner,et al.  Actionable, pathogenic incidental findings in 1,000 participants' exomes. , 2013, American journal of human genetics.

[35]  Claire Redin,et al.  XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. , 2013, American journal of human genetics.

[36]  Megan Allyse,et al.  Not-so-incidental findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing. , 2013, Trends in biotechnology.

[37]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[38]  B. Knoppers,et al.  Whole-genome sequencing in health care , 2013, European Journal of Human Genetics.

[39]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[40]  B. V. van Bon,et al.  Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.

[41]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[42]  E. Génin,et al.  The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening , 2009, Journal of Medical Genetics.